Filing Details

Accession Number:
0001209191-13-021277
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-04-12 17:05:46
Reporting Period:
2013-04-10
Filing Date:
2013-04-12
Accepted Time:
2013-04-12 17:05:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1314760 P William Forbes 8510 Colonnade Center Drive
Raleigh NC 27615
Evp Research&Devel & Cdo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-04-10 13,000 $17.53 80,191 No 4 M Direct
Common Stock Disposition 2013-04-10 8,673 $49.37 71,518 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Buy Common Stock Disposition 2013-04-10 13,000 $0.00 13,000 $17.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,200 2014-12-16 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 6,250 6,250 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 6,250 6,250 Direct
Footnotes
  1. The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2013.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.04 to $49.59, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to the Form 4.
  3. Options are 100% vested.